John Joseph Johnston Sells 5,000 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock

MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston sold 5,000 shares of the firm’s stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $4.41, for a total value of $22,050.00. Following the transaction, the director now owns 120,583 shares in the company, valued at $531,771.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

John Joseph Johnston also recently made the following trade(s):

• On Friday, January 26th, John Joseph Johnston sold 5,000 shares of MaxCyte stock. The stock was sold at an average price of $5.12, for a total value of $25,600.00.

MaxCyte Price Performance

Shares of MXCT traded down $0.13 during trading hours on Thursday, reaching $4.19. 609,632 shares of the company’s stock traded hands, compared to its average volume of 678,650. The firm has a market capitalization of $436.18 million, a price-to-earnings ratio of -11.27 and a beta of 1.36. MaxCyte, Inc. has a twelve month low of $2.45 and a twelve month high of $5.55. The business’s fifty day simple moving average is $4.64 and its two-hundred day simple moving average is $4.20.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Swiss National Bank grew its holdings in MaxCyte by 7.9% during the first quarter. Swiss National Bank now owns 155,000 shares of the company’s stock worth $1,083,000 after acquiring an additional 11,400 shares during the period. ProShare Advisors LLC acquired a new position in MaxCyte during the first quarter worth about $204,000. JPMorgan Chase & Co. grew its holdings in MaxCyte by 7.6% during the first quarter. JPMorgan Chase & Co. now owns 108,886 shares of the company’s stock worth $762,000 after acquiring an additional 7,647 shares during the period. MetLife Investment Management LLC grew its holdings in MaxCyte by 55.4% during the first quarter. MetLife Investment Management LLC now owns 56,124 shares of the company’s stock worth $392,000 after acquiring an additional 20,012 shares during the period. Finally, Rhumbline Advisers boosted its position in shares of MaxCyte by 11.9% in the 1st quarter. Rhumbline Advisers now owns 104,878 shares of the company’s stock valued at $733,000 after purchasing an additional 11,184 shares during the period. 68.81% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MXCT has been the topic of several research analyst reports. Craig Hallum assumed coverage on MaxCyte in a research note on Wednesday, November 29th. They set a “buy” rating and a $7.00 price objective on the stock. William Blair reaffirmed an “outperform” rating on shares of MaxCyte in a research report on Wednesday, March 13th. BTIG Research dropped their target price on MaxCyte from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, March 13th. Finally, Stephens reaffirmed an “overweight” rating and issued a $11.00 target price on shares of MaxCyte in a research report on Wednesday, March 13th.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.